Lipoprotein lipase DNA methylation in the adipose tissue of patients with persistent chylomicronemia
Journal of Clinical Lipidology · 2026
DOI: 10.1016/j.jacl.2026.02.015 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Lipidology, 2026. Verfasst von Miriam Larouche und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Université de Montréal and ECOGENE-21 Canada (Larouche, Brisson, and Gaudet). Hauptthemen laut MEDLINE: Lipoprotein Lipase, DNA Methylation, Adipose Tissue, Hyperlipoproteinemia Type I. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND: Persistent chylomicronemia (PC) is a rare condition characterized by plasma triglyceride concentration persistently >10 mmol/L despite treatment, reflecting a lack of lipoprotein lipase (LPL) bioavailability. PC encompasses patients with the familial chylomicronemia syndrome (FCS) and patients with multifactorial PC. Life habits and environmental factors are known modulators of DNA methylation (DNAme), which can influence access to the LPL gene and possibly contribute to the expression of PC. OBJECTIVE: To compare LPL DNAme in blood and adipose tissue of patients with PC or other causes of hypertriglyceridemia (HTG) and normotriglyceridemic controls. METHODS: DNA was extracted from blood and adipose tissue in 186 participants: 31 with PC (21 FCS, 10 multifactorial PC), 125 with HTG, and 30 controls. DNAme was measured using pyrosequencing at 22 cytosine-phosphate-guanine sites (CpGs) located in the promoter and between the first exons of the LPL gene. Differences in LPL DNAme were assessed according to the genotype and severity of HTG. RESULTS: No difference in LPL DNAme was observed in blood samples. In adipose tissues, patients with FCS were significantly less methylated at 2 CpGs located in the LPL gene body compared with other genotypes (Δϐ = 2.85% and 3.78%, P = .011). When DNAme was analyzed according to HTG severity, the same CpGs were less methylated in patients with PC of any cause compared with other groups (Δϐ = 4.55%, P = .002; Δϐ = 7.70%, P < .001). CONCLUSION: In this study, the LPL DNAme signature in adipose tissue differed in patients with PC compared with others, highlighting that different factors might contribute to PC and its associated risks.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Université de Montréal and ECOGENE-21 Canada (Larouche, Brisson, and Gaudet).
- Département des sciences fondamentales, Université du Québec à Chicoutimi Canada (Laprise); Centre intersectoriel en santé durable, Université du Québec à Chicoutimi Canada (Laprise); Centre intégré universitaire de san…
- Department of Medicine, Université de Montréal and ECOGENE-21 Canada (Larouche, Brisson, and Gaudet). Electronic address: daniel.gaudet@umontreal.ca.
Zitieren
APA
Larouche, M., Brisson, D., Laprise, C., & Gaudet, D. (2026). Lipoprotein lipase DNA methylation in the adipose tissue of patients with persistent chylomicronemia. Journal of Clinical Lipidology. https://doi.org/10.1016/j.jacl.2026.02.015
Vancouver
Larouche M, Brisson D, Laprise C, Gaudet D. Lipoprotein lipase DNA methylation in the adipose tissue of patients with persistent chylomicronemia. Journal of Clinical Lipidology. 2026. doi:10.1016/j.jacl.2026.02.015
BibTeX
@article{Larouche2026,
author = {Larouche, Miriam and Brisson, Diane and Laprise, Catherine and Gaudet, Daniel},
title = {Lipoprotein lipase DNA methylation in the adipose tissue of patients with persistent chylomicronemia},
journal = {Journal of Clinical Lipidology},
year = {2026},
doi = {10.1016/j.jacl.2026.02.015}
}
EUVIMED